PI3K/mTOR Inhibitor-11

• UNSPSC Description:

  PI3K/mTOR Inhibitor-11 is an orally active PI3K/mTOR inhibitor (IC50: 3.5, 4.6, and 21.3 nM for PI3Kα, PI3Kδ, and mTOR). PI3K/mTOR Inhibitor-11 regulates the PI3K/AKT/mTOR signaling pathway by inhibiting the phosphorylation of AKT and S6 proteins. PI3K/mTOR Inhibitor-11 can be used in the research of cancers[1].

• Target Antigen:

  mTOR; PI3K

• Type:

  Reference compound

• Related Pathways:

  PI3K/Akt/mTOR

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/pi3k-mtor-inhibitor-11.html

• Solubility:

  DMSO : 40 mg/mL (ultrasonic;warming;heat to 60°C)

• Smiles:

  CC(C1=NC=C(N2C(C)=NC3=C2C4=CC(C5=CN=C(NC=C6)C6=C5)=CC=C4N=C3)C=C1)(C)C#N

• Molecular Weight:

  443.50

• References & Citations:

  [1]Yang J, et al. Discovery of 2-Methyl-2-(4-(2-methyl-8-(1H-pyrrolo[2,3-b]pyridin-6-yl)-1H-naphtho[1,2-d]imidazol-1-yl)phenyl)propanenitrile as a Novel PI3K/mTOR Inhibitor with Enhanced Antitumor Efficacy In Vitro and In Vivo. J Med Chem. 2022 Oct 13;65(19):12781-12801.

• Shipping Conditions:

  Room Temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  2845104-25-6